Brief Report: Metformin for Antipsychotic-Induced Weight Gain in Youth with Autism Spectrum Disorder

Antipsychotic treatment in youth with autism spectrum disorder (ASD) is becoming increasingly common, placing individuals at risk for antipsychotic-induced weight gain and associated complications. Metformin hydrochloride, a biguanide medication FDA-approved for treatment of type-2 diabetes in youth...

Full description

Saved in:
Bibliographic Details
Published in:Journal of autism and developmental disorders 2017-07, Vol.47 (7), p.2290-2294
Main Authors: Wink, Logan K., Adams, Ryan, Pedapati, Ernest V., Dominick, Kelli C., Fox, Emma, Buck, Catherine, Erickson, Craig A.
Format: Article
Language:English
Subjects:
Adolescent
Antidiabetics
Antipsychotic agents
Antipsychotic Agents - adverse effects
Antipsychotic Agents - therapeutic use
Antipsychotics
Autism
Autism Spectrum Disorder - complications
Autism Spectrum Disorder - drug therapy
Autistic children
Behavioral Science and Psychology
Body mass index
Brief Report
Care and treatment
Child
Child and School Psychology
Complications and side effects
Diabetes
Diabetes mellitus
Drug Therapy
Efficacy
Female
Humans
Hypoglycemic Agents - administration & dosage
Hypoglycemic Agents - adverse effects
Hypoglycemic Agents - therapeutic use
Induced
Male
Metformin
Metformin - administration & dosage
Metformin - adverse effects
Metformin - therapeutic use
Neurosciences
Obesity
Outcomes of Treatment
Overweight - drug therapy
Overweight - etiology
Overweight - prevention & control
Overweight persons
Patient outcomes
Pediatrics
Pervasive Developmental Disorders
Psychology
Psychotropic drugs
Public Health
Scores
Weight Gain
Youth
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Antipsychotic treatment in youth with autism spectrum disorder (ASD) is becoming increasingly common, placing individuals at risk for antipsychotic-induced weight gain and associated complications. Metformin hydrochloride, a biguanide medication FDA-approved for treatment of type-2 diabetes in youth, may hold promise for treatment of antipsychotic-induced weight gain in youth with ASD. In this report we assess the long-term impact of metformin on antipsychotic-associated weight gain in a naturalistic sample of 53 youth with ASD. Results indicate that treatment with metformin stabilized BMI z-score over a nearly 2 year mean treatment period. Further work is indicated to determine the safety and efficacy of metformin treatment in youth with ASD, as well as predictors of response as a treatment for antipsychotic-induced weight gain.
ISSN:0162-3257
1573-3432
DOI:10.1007/s10803-017-3132-2